Boosting Immunity with Special Nanoparticles
RIG-I Activating Nanoparticles for Immunopotentiation
This research explores how tiny particles can activate a natural defense system in our bodies to help fight or prevent various diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11169002 on NIH RePORTER |
What this research studies
Our bodies have a natural defense system, called the innate immune system, that can be trained to fight off illnesses. One important part of this system is a protein called RIG-I, which acts like a sensor for harmful invaders. When RIG-I is activated, it triggers a strong protective response, but getting the right signals to it has been difficult. This project uses specially designed 'nanoparticles' – tiny carriers – to deliver these signals directly to RIG-I inside our cells. These nanoparticles are engineered to be more effective at reaching and activating RIG-I, aiming to create a powerful new way to strengthen our immune response against various health threats.
Who could benefit from this research
Good fit: This foundational research is not yet recruiting patients, but future applications could benefit individuals with various diseases that respond to immune system activation.
Not a fit: Patients whose conditions do not involve the RIG-I pathway or immune system activation may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could lead to new treatments or ways to prevent a wide range of diseases by enhancing the body's own immune defenses.
How similar studies have performed: While the concept of activating RIG-I for immune benefits is recognized, these specific nanoparticles are a novel approach being developed and optimized.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Wilson, John Tanner — Vanderbilt University
- Study coordinator: Wilson, John Tanner
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.